Tag: Bavencio

September 27, 2019 Off

Merck, Pfizer present avelumab’s activity in tumors treatment

Merck’s biopharmaceutical branch, EMD Serono, and Pfizer will present clinical activity of treatment with Bavencio across multiple tumor types and patient populations at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain.

February 11, 2019 Off

Immunicium to treat cancer patients with its lead in-development-product, ILIAD

By Dino Mustafić

Immunicum has treated the first patient in the Phase Ib/II clinical trial of its lead product in development, ilixadencel (ILIAD), in combination with checkpoint inhibitors (CPIs) in three cancer indications: head and neck cancer, non-small cell lung cancer and gastric cancer.